aztreonam has been researched along with Urinary Tract Infections in 88 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A comparative study has been performed to evaluate the clinical efficacy and safety of aztreonam in the treatment of urinary tract infections with systemic affectation, in a group of patients who showed a relative contraindication to be treated with aminoglycosides." | 9.07 | [Aztreonam as monotherapy in urinary tract infections with a systemic repercussion in patients with a relative contraindication for the use of aminoglycosides]. ( Fernández-Cruz, A; García, C; Mesa, N; Pedrajas, JM; Pieltain, R; Pontes, JC; Ramón, P, 1993) |
| "A prospective, randomized trial was conducted to compare the efficacy of aztreonam, a monobactam antibiotic, and gentamicin in the treatment of serious urinary tract infections." | 9.07 | A comparative trial of aztreonam versus gentamicin in the treatment of urinary tract infections. ( Kendall, SW; Waller, DA; Whelan, P, 1992) |
| "The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 isolates from urological in-patients with complicated and/or hospital acquired urinary tract infections (UTI)." | 9.06 | Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections. ( Dette, GA; Grobecker, H; Kees, F; Knothe, H; Naber, KG, 1986) |
| "A well-controlled comparative study was conducted in order to evaluate the efficacy, safety and usefulness of the monobactam antibiotic aztreonam (AZT) in complicated urinary tract infections (UTI) using cefoperazone (CPZ) as the control drug." | 9.06 | [Well-controlled comparative study on aztreonam and cefoperazone in the treatment of complicated urinary tract infections]. ( Kawamura, N; Kishi, H; Kumamoto, Y; Kumon, H; Naide, Y; Niijima, T; Nishiura, T; Ohkoshi, M; Ohmori, H; Sakai, S, 1986) |
| "We have compared the effects of aztreonam and placebo in the prevention of urinary tract infections (UTI) in elderly hospitalized patients who needed urethral catheterization." | 9.06 | A single dose of aztreonam in the prevention of urinary tract infections in elderly catheterized patients. ( Bodini, C; Bossoni, S; Cravarezza, P; Girelli, A; Giustina, A; Romanelli, G; Turano, A, 1990) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 9.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "Carumonam and gentamicin were compared in a prospective, randomized study of 52 patients with complicated urinary tract infections." | 9.06 | Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections. ( Bakker, LJ; Hoepelman, AI; Verhoef, J, 1988) |
| "A multicenter comparative study was carried out to evaluate the efficacy of aztreonam and gentamicin in 186 patients with symptomatic renal or urinary tract infections." | 9.06 | Multicenter comparative study of aztreonam and gentamicin in the treatment of renal and urinary tract infections. ( Albertazzi, A; Bonadio, M; Fusaroli, M; Lotti, T; Miano, L; Salvia, G; Sasdelli, M; Ventriglia, L; Villa, G; Zucchelli, P, 1989) |
| "A multicenter trial involving several urologic units in Italy provided pooled data on 1,427 patients with urinary tract infections to evaluate the efficacy and safety of aztreonam, a new monobactam antibiotic." | 9.06 | Aztreonam in the treatment of urinary tract infections: a multicenter trial. ( Cortecchia, V; Martelli, A; Ventriglia, L, 1989) |
| "The clinical effectiveness and safety of Aztreonam (AZT) were studied in 55 patients with complicated urinary tract infections." | 9.06 | [Clinical reevaluation of aztreonam (AZT) on urinary tract infections]. ( Iguti, M; Kadowaki, T; Kanda, H; Kataoka, K; Kawamura, M; Kohri, K; Kurita, T; Mitsubayashi, S; Nagi, N; Sakaguti, H, 1989) |
| "Aztreonam (AZT, Azactam) was given to 176 patients with complicated urinary tract infections (UTI), of whom 110 cases satisfied with the "Criteria of UTI Committee for the Evaluation of Drug Efficacy in the UTI (3rd Ed." | 9.06 | [Clinical evaluation of aztreonam (AZT) in the treatment of complicated urinary tract infections]. ( Honda, M; Iwao, N; Kameoka, H; Kishimoto, T; Miyoshi, S; Mizutani, S; Nakamura, T; Sakurai, T; Wakatsuki, A; Yano, H, 1989) |
| "Aztreonam (AZT) (2 g daily) was intravenously administered for 5 to 7 days to 65 patients with complicated urinary tract infections (UTI)." | 9.06 | [Clinical efficacy of aztreonam in patients with complicated urinary tract infections]. ( Kageyama, Y; Kobayashi, N; Kura, N; Nakame, Y; Negishi, T; Saitoh, H; Suwata, J; Uchijima, Y; Yamada, T; Yoshida, K, 1988) |
| "52 patients with serious urinary tract infections were randomised to receive either aztreonam (35) or gentamicin (17)." | 9.05 | Aztreonam compared with gentamicin for treatment of serious urinary tract infections. ( Appelbaum, PC; Lombard, JS; Moyer, JE; Sattler, FR; Schramm, M, 1984) |
| "The in vivo efficacy and safety of aztreonam compared to that of cefamandole was randomly and prospectively studied in the treatment of 30 patients suffering from recurrent urinary tract infections with a patient ratio of 2 aztreonam to 1 cefamandole." | 9.05 | Aztreonam versus cefamandole in the treatment of urinary tract infections. ( Daikos, G; el Messidi, M; Galanakis, N; Giamarellou, H; Kanellakopoulou, K; Koratzanis, G; Papoulias, G, 1984) |
| "A "bolus dose" of aztreonam was used to treat a sample group of 46 neonates suffering from urinary tract infections caused by bacteria thought to be sensitive to aztreonam." | 7.68 | [The efficacy of aztreonam in a "bolus dose" in the therapy of urinary tract infections in neonates]. ( Bertino, E; Cavo, L; Fabris, C; Licata, D; Martano, C, 1993) |
| "The clinical efficacy and safety of aztreonam were studied in 30 patients suffering from urinary tract infections caused by gram-negative bacteria." | 7.67 | Use of aztreonam in patients suffering from urinary tract infections with contraindications for the use of aminoglycosides. ( Alessandria, M; Fraschini, F; Gattei, G; Scaglione, F, 1986) |
| "Carumonam is a new monobactam antibiotic with potent activity against gram-negative aerobes." | 6.66 | Carumonam versus ceftazidime for urinary tract infections. ( Cassano, K; Edelstein, H; McCabe, R; Oster, S, 1988) |
| "In the group with respiratory infections, the mean duration of treatment was 9." | 6.65 | Clinical experience with aztreonam in urinary and respiratory tract infections. ( Donohoe, JF; Hollingsworth, JA; Hone, R; Keelan, PJ, 1984) |
| "Urinary tract infections are common among pediatric patients, occurring in approximately 2% of children within the first 5 to 10 years of life." | 6.38 | The role of aztreonam in treatment of complicated urinary tract infections in children. ( Kline, MW, 1989) |
| "Aztreonam was administered to 30 patients, ages 0." | 5.27 | Aztreonam in the treatment of severe urinary tract infections in pediatric patients. ( Assael, BM; Boccazzi, A; Colombo, R; Crossignani, RM; Garlaschi, L; Rancilio, L; Rusconi, F, 1986) |
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 5.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "Episodes treated were 39 urinary tract infections (12 of them with concomitant bacteremia), 2 soft tissue infections, 8 patients with osteomyelitis (1 with concomitant bacteremia), and one episode of pneumonia." | 5.27 | Evaluation of aztreonam in the treatment of severe bacterial infections. ( Bouza, E; García de la Torre, M; Guerrero, A; Hellín, T; Martínez-Beltrán, J; Rodríguez-Créixems, M; Romero-Vivas, J, 1985) |
| "The combination of carumonam (CRMN) and cefotiam (CTM), expected to have a broader spectrum of coverage in connection with urinary tract infections, was evaluated for its effectiveness and safety at the Department of Urology, Osaka University Hospital and 17 affiliated hospitals." | 5.07 | [Clinical evaluation of the combination of carumonam and cefotiam in the treatment of complicated urinary tract infection]. ( Ihara, Y; Iwao, N; Kishimoto, T; Kuroda, H; Mizutani, S; Nakano, E; Seguchi, T; Sonoda, T; Takatera, H; Yano, H, 1991) |
| "The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 isolates from urological in-patients with complicated and/or hospital acquired urinary tract infections (UTI)." | 5.06 | Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections. ( Dette, GA; Grobecker, H; Kees, F; Knothe, H; Naber, KG, 1986) |
| "We have compared the effects of aztreonam and placebo in the prevention of urinary tract infections (UTI) in elderly hospitalized patients who needed urethral catheterization." | 5.06 | A single dose of aztreonam in the prevention of urinary tract infections in elderly catheterized patients. ( Bodini, C; Bossoni, S; Cravarezza, P; Girelli, A; Giustina, A; Romanelli, G; Turano, A, 1990) |
| "Carumonam (CRMN), the first monobactam antibiotic in Japan, has excellent activity against gram-negative bacteria and is useful in the treatment of urinary tract infections." | 5.06 | [Clinical evaluation of the combination of carumonam and fosfomycin in the treatment of complicated urinary tract infection]. ( Hirano, J; Hirano, K; Imamura, A; Ishii, N; Kakizaki, H; Mitobe, K; Murakami, S; Saito, M; Suzuki, K; Takamizawa, A, 1990) |
| "A well-controlled comparative study was conducted in order to evaluate the efficacy, safety and usefulness of the monobactam antibiotic aztreonam (AZT) in complicated urinary tract infections (UTI) using cefoperazone (CPZ) as the control drug." | 5.06 | [Well-controlled comparative study on aztreonam and cefoperazone in the treatment of complicated urinary tract infections]. ( Kawamura, N; Kishi, H; Kumamoto, Y; Kumon, H; Naide, Y; Niijima, T; Nishiura, T; Ohkoshi, M; Ohmori, H; Sakai, S, 1986) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 5.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "A multicenter comparative study was carried out to evaluate the efficacy of aztreonam and gentamicin in 186 patients with symptomatic renal or urinary tract infections." | 5.06 | Multicenter comparative study of aztreonam and gentamicin in the treatment of renal and urinary tract infections. ( Albertazzi, A; Bonadio, M; Fusaroli, M; Lotti, T; Miano, L; Salvia, G; Sasdelli, M; Ventriglia, L; Villa, G; Zucchelli, P, 1989) |
| "A multicenter trial involving several urologic units in Italy provided pooled data on 1,427 patients with urinary tract infections to evaluate the efficacy and safety of aztreonam, a new monobactam antibiotic." | 5.06 | Aztreonam in the treatment of urinary tract infections: a multicenter trial. ( Cortecchia, V; Martelli, A; Ventriglia, L, 1989) |
| "Carumonam and gentamicin were compared in a prospective, randomized study of 52 patients with complicated urinary tract infections." | 5.06 | Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections. ( Bakker, LJ; Hoepelman, AI; Verhoef, J, 1988) |
| "Aztreonam (AZT) (2 g daily) was intravenously administered for 5 to 7 days to 65 patients with complicated urinary tract infections (UTI)." | 5.06 | [Clinical efficacy of aztreonam in patients with complicated urinary tract infections]. ( Kageyama, Y; Kobayashi, N; Kura, N; Nakame, Y; Negishi, T; Saitoh, H; Suwata, J; Uchijima, Y; Yamada, T; Yoshida, K, 1988) |
| "52 patients with serious urinary tract infections were randomised to receive either aztreonam (35) or gentamicin (17)." | 5.05 | Aztreonam compared with gentamicin for treatment of serious urinary tract infections. ( Appelbaum, PC; Lombard, JS; Moyer, JE; Sattler, FR; Schramm, M, 1984) |
| "Multicenter trials were conducted to determine the safety and efficacy of aztreonam in the treatment of patients with gram-negative bacterial infections." | 5.05 | Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. ( Bendush, CB; Henry, SA, 1985) |
| "Of the new antimicrobials available for the treatment of urinary tract infections (UTIs), aztreonam and imipenem/cilastatin represent two structurally unique, but distinct, classes of beta-lactam antibiotics." | 4.77 | UTIs and two new antibiotics in the elderly. ( Jones, SR; Kimbrough, R, 1988) |
| "The present study was carried out with the aim of comparing the microbiological and clinical efficacy of norfloxacin, cinoxacin and aztreonam in urinary tract infections." | 3.67 | Treatment of urinary infections: clinical perspectives. ( Carlone, NA; Fontana, G; Laudi, M; Savoia, D, 1987) |
| "Aztreonam was administered to 20 children diagnosed as having any of the following infections: urinary tract infection, pneumonia, meningitis, and abscess of the appendix." | 3.67 | Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients. ( Arango, A; Benítez, G; Castrillón, AL; Harry, N; Mejía, GI; Restrepo, F; Trujillo, H, 1989) |
| "Aztreonam (AZT) was given intravenously to 20 children with the following acute bacterial infections: 13 cases of bronchopneumonia, 5 cases of urinary tract infection, 1 case of cervical lymphadenitis with acute tonsillitis and 1 case of acute enteritis." | 3.67 | [Clinical experience with aztreonam in the pediatric field]. ( Aihara, R; Kobashi, H; Nishioka, A; Okamoto, T; Oohara, K, 1985) |
| " An adequate standard dosage of aztreonam could be established as 3-4 g/day in compromised patients, and it should be combined with gram-positive coverage when used empirically." | 2.66 | A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. ( Bosch-Perez, A; Rabinad, E, 1989) |
| "Carumonam is a new monobactam antibiotic with potent activity against gram-negative aerobes." | 2.66 | Carumonam versus ceftazidime for urinary tract infections. ( Cassano, K; Edelstein, H; McCabe, R; Oster, S, 1988) |
| "In the group with respiratory infections, the mean duration of treatment was 9." | 2.65 | Clinical experience with aztreonam in urinary and respiratory tract infections. ( Donohoe, JF; Hollingsworth, JA; Hone, R; Keelan, PJ, 1984) |
| " Azthreonam was given intramuscularly, as monotherapy, in a daily dosage of 2 g, in two divided doses, for 10 to 29 days (mean: 28 days)." | 2.65 | [Clinical evaluation of azthreonam in severe urinary tract infections]. ( Acar, JF; Guibert, J; Miegi, M, 1984) |
| "Aztreonam is a synthetic monobactam antibiotic that has excellent activity against aerobic gram-negative bacilli." | 2.38 | Aztreonam. ( Clark, P, 1992) |
| "Aztreonam has proven to be effective, safe therapy for serious and life-threatening infections caused by multiresistant aerobic gram negative bacteria." | 2.37 | Aztreonam: the first monobactam. ( Neu, HC, 1988) |
| " Renal insufficiency may significantly impair the elimination of aztreonam, thus requiring modification of the dosage regimen." | 2.37 | Review of the clinical pharmacology of the monobactam antibiotic aztreonam. ( Swabb, EA, 1985) |
| "Aztreonam was administered to 25 neonates (16 term, 9 premature) with clinically and bacteriologically proved gram-negative infections." | 1.28 | Successful response of severe neonatal gram-negative infection to treatment with aztreonam. ( Constantopoulos, A; Loupa, H; Papoulias, G; Thomaidou, L, 1989) |
| "Treatment with aztreonam (1 g i." | 1.28 | [Aztreonam and aminoglycosides in the therapy of urinary infections associated with renal calculosis]. ( Cipriani, P; Coen, G; Giordano, A; Mazzaferro, S; Nazzaro, L; Petta, S; Reale, MG; Smacchi, A, 1989) |
| " Tolerance to the drug was good in both groups, and in no instance did side effects necessitate modification of the dosing regimen." | 1.28 | The clinical use of aztreonam. ( Car, V; Krznar, B; Schönwald, S; Schoss-Vidensek, Z, 1989) |
| "Aztreonam was active against Pseudomonas spp." | 1.27 | In vitro activity of aztreonam, cefuroxime and ceftazidime against gram-negative rods isolated from hospital patients with urinary tract infection. ( Felmingham, D; Grüneberg, RN; O'Hare, MD; Ridgway, GL; Robbins, MJ; Webb, G, 1987) |
| "Aztreonam was given i." | 1.27 | Aztreonam in the treatment of serious gram-negative infections in the elderly. ( Deger, F; Douchamps, J; Freschi, E; Herchuelz, A; Nève, P; Thys, JP, 1988) |
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 1.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "Episodes treated were 39 urinary tract infections (12 of them with concomitant bacteremia), 2 soft tissue infections, 8 patients with osteomyelitis (1 with concomitant bacteremia), and one episode of pneumonia." | 1.27 | Evaluation of aztreonam in the treatment of severe bacterial infections. ( Bouza, E; García de la Torre, M; Guerrero, A; Hellín, T; Martínez-Beltrán, J; Rodríguez-Créixems, M; Romero-Vivas, J, 1985) |
| "Aztreonam was administered to 30 patients, ages 0." | 1.27 | Aztreonam in the treatment of severe urinary tract infections in pediatric patients. ( Assael, BM; Boccazzi, A; Colombo, R; Crossignani, RM; Garlaschi, L; Rancilio, L; Rusconi, F, 1986) |
| "Aztreonam was the first compound to emerge that fulfilled the objectives of the program." | 1.27 | Aztreonam: the first monobactam. ( Bonner, DP; Sykes, RB, 1985) |
| "Aztreonam is a novel antimicrobial agent belonging to the monobactam class of antibiotics." | 1.27 | Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. ( Neu, HC; Scully, BE, 1985) |
| "Aztreonam was well tolerated." | 1.27 | Treatment of gram-negative infections with aztreonam. ( Lee, TJ; Simons, WJ, 1985) |
| "Aztreonam is a monocyclic beta-lactam antibiotic that inhibits aerobic gram-negative bacilli, including beta-lactamase-producing species." | 1.27 | Current state of infectious diseases--potential areas of directed therapy with aztreonam. ( Neu, HC, 1985) |
| "Aztreonam was administered to 15 patients with complicated UTI admitted to our Hospitals between July, 1984 and January, 1985." | 1.27 | [Clinical evaluation of aztreonam for complicated urinary tract infection]. ( Aoki, S; Moriguchi, R; Nagakubo, I; Yamagoshi, T, 1985) |
| "Clinical efficacy of AZT for 22 respiratory tract infections, 5 urinary tract infections and 2 gastrointestinal infections was "excellent" for 19 cases (65." | 1.27 | [Clinical study on aztreonam in pediatrics]. ( Kida, K; Matsuda, H; Murase, M; Niino, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 64 (72.73) | 18.7374 |
| 1990's | 15 (17.05) | 18.2507 |
| 2000's | 2 (2.27) | 29.6817 |
| 2010's | 2 (2.27) | 24.3611 |
| 2020's | 5 (5.68) | 2.80 |
| Authors | Studies |
|---|---|
| Jalil, MB | 1 |
| Al Atbee, MYN | 1 |
| Afsharikhah, S | 1 |
| Ghanbarpour, R | 1 |
| Mohseni, P | 1 |
| Adib, N | 1 |
| Bagheri, M | 1 |
| Jajarmi, M | 1 |
| Faiza Asghar, - | 1 |
| Sardar Muhammad, - | 1 |
| Aftab Ahmad Anjum, - | 1 |
| Tehreem Ali, - | 1 |
| Abdul Shaheed Asghar, - | 1 |
| Sobia Naureen, - | 1 |
| Rabia Manzoor, - | 1 |
| Mura, M | 1 |
| Longo, B | 1 |
| Andreini, R | 1 |
| Sbrana, F | 1 |
| Ripoli, A | 1 |
| Andreoli, E | 1 |
| Sani, S | 1 |
| Tumbarello, M | 1 |
| Meini, S | 1 |
| Miller, J | 1 |
| Hall, B | 1 |
| Wilson, K | 1 |
| Cobian, J | 1 |
| Tian, GB | 1 |
| Huang, YM | 1 |
| Fang, ZL | 1 |
| Qing, Y | 1 |
| Zhang, XF | 1 |
| Huang, X | 1 |
| Wang, JT | 1 |
| Chen, PC | 1 |
| Chang, SC | 1 |
| Shiau, YR | 1 |
| Wang, HY | 1 |
| Lai, JF | 1 |
| Huang, IW | 1 |
| Tan, MC | 1 |
| Lauderdale, TL | 1 |
| Kumamoto, Y | 2 |
| Tsukamoto, T | 1 |
| Matsukawa, M | 1 |
| Kunishima, Y | 1 |
| Hirose, T | 1 |
| Shigeta, S | 1 |
| Yamaguti, O | 1 |
| Ishibashi, K | 1 |
| Suzutani, T | 1 |
| Yoshida, H | 1 |
| Imafuku, Y | 1 |
| Murai, M | 1 |
| Watanabe, K | 1 |
| Kobayashi, Y | 1 |
| Uchida, H | 1 |
| Matsuda, S | 1 |
| Sato, S | 1 |
| Fujime, M | 1 |
| Fujita, K | 1 |
| Igari, J | 1 |
| Oguri, T | 1 |
| Yamaguchi, K | 1 |
| Furuya, N | 1 |
| Deguchi, T | 1 |
| Ishihara, S | 1 |
| Ooe, H | 1 |
| Oka, T | 1 |
| Kitamura, M | 1 |
| Fukuhara, Y | 1 |
| Kamidono, S | 1 |
| Arakawa, S | 1 |
| Kumon, H | 2 |
| Monden, K | 1 |
| Matsumoto, T | 1 |
| Muratani, T | 1 |
| Naito, S | 1 |
| Egashira, T | 1 |
| Konishi, T | 1 |
| Kohno, S | 1 |
| Hirakata, Y | 1 |
| Kondo, A | 1 |
| Matsuda, J | 1 |
| Nakano, M | 1 |
| Taneja, N | 1 |
| Rao, P | 1 |
| Arora, J | 1 |
| Dogra, A | 1 |
| Sattler, FR | 1 |
| Moyer, JE | 1 |
| Schramm, M | 1 |
| Lombard, JS | 1 |
| Appelbaum, PC | 1 |
| Guibert, J | 1 |
| Acar, JF | 1 |
| Miegi, M | 1 |
| Hollingsworth, JA | 1 |
| Donohoe, JF | 1 |
| Hone, R | 1 |
| Keelan, PJ | 1 |
| Giamarellou, H | 1 |
| Koratzanis, G | 1 |
| Kanellakopoulou, K | 1 |
| Galanakis, N | 1 |
| Papoulias, G | 2 |
| el Messidi, M | 1 |
| Daikos, G | 1 |
| Castelao, AM | 1 |
| Soto, K | 1 |
| Grinyó, JM | 1 |
| Gilvernet, S | 1 |
| Serón, D | 1 |
| Torras, J | 1 |
| Riera, L | 1 |
| Cruzado, JM | 1 |
| Alsina, J | 1 |
| Fabris, C | 1 |
| Licata, D | 1 |
| Bertino, E | 1 |
| Cavo, L | 1 |
| Martano, C | 1 |
| Cunha, BA | 1 |
| Pedrajas, JM | 1 |
| Pieltain, R | 1 |
| Mesa, N | 1 |
| Ramón, P | 1 |
| García, C | 1 |
| Pontes, JC | 1 |
| Fernández-Cruz, A | 1 |
| Waller, DA | 1 |
| Kendall, SW | 1 |
| Whelan, P | 1 |
| Sakata, Y | 1 |
| Sawada, Y | 1 |
| Kuroe, K | 1 |
| Nakaji, S | 1 |
| Takami, H | 1 |
| Tsushima, K | 1 |
| Saito, S | 1 |
| Ogasawara, H | 1 |
| Shinagawa, H | 1 |
| Soma, N | 1 |
| Clark, P | 1 |
| Fayed, DF | 1 |
| Dahmash, NS | 1 |
| Saddique, AA | 1 |
| Shibl, AM | 1 |
| Gomez-Alferez, A | 1 |
| Baquero, F | 1 |
| Canton, R | 1 |
| Loza, E | 1 |
| Martinez-Beltran, J | 2 |
| Melekos, MD | 1 |
| Skoutelis, A | 1 |
| Chryssanthopoulos, C | 1 |
| Bassaris, HP | 1 |
| Bosso, JA | 1 |
| Black, PG | 1 |
| Sonoda, T | 1 |
| Nakano, E | 1 |
| Seguchi, T | 1 |
| Yano, H | 2 |
| Kuroda, H | 1 |
| Ihara, Y | 1 |
| Kishimoto, T | 2 |
| Takatera, H | 1 |
| Mizutani, S | 2 |
| Iwao, N | 2 |
| Obana, Y | 1 |
| Murakami, T | 1 |
| Kuzui, H | 1 |
| Nishino, T | 1 |
| Romanelli, G | 1 |
| Giustina, A | 1 |
| Cravarezza, P | 1 |
| Bossoni, S | 1 |
| Bodini, C | 1 |
| Girelli, A | 1 |
| Turano, A | 1 |
| Kakizaki, H | 1 |
| Ishii, N | 1 |
| Murakami, S | 1 |
| Suzuki, K | 1 |
| Takamizawa, A | 1 |
| Hirano, J | 1 |
| Mitobe, K | 1 |
| Saito, M | 1 |
| Hirano, K | 1 |
| Imamura, A | 1 |
| Coen, G | 1 |
| Nazzaro, L | 1 |
| Cipriani, P | 1 |
| Giordano, A | 1 |
| Mazzaferro, S | 1 |
| Petta, S | 1 |
| Reale, MG | 1 |
| Smacchi, A | 1 |
| Puppo, P | 1 |
| Germinale, F | 1 |
| De Rose, AF | 1 |
| Rabinad, E | 2 |
| Bosch-Perez, A | 1 |
| Albertazzi, A | 1 |
| Bonadio, M | 1 |
| Fusaroli, M | 1 |
| Lotti, T | 1 |
| Miano, L | 1 |
| Salvia, G | 1 |
| Sasdelli, M | 1 |
| Villa, G | 1 |
| Zucchelli, P | 1 |
| Ventriglia, L | 3 |
| Martelli, A | 2 |
| Cortecchia, V | 2 |
| Kohri, K | 1 |
| Kurita, T | 1 |
| Sakaguti, H | 1 |
| Kadowaki, T | 1 |
| Iguti, M | 1 |
| Kanda, H | 1 |
| Nagi, N | 1 |
| Kataoka, K | 1 |
| Kawamura, M | 1 |
| Mitsubayashi, S | 1 |
| Kline, MW | 1 |
| Miyoshi, S | 1 |
| Kameoka, H | 1 |
| Sakurai, T | 1 |
| Wakatsuki, A | 1 |
| Nakamura, T | 1 |
| Honda, M | 1 |
| Constantopoulos, A | 1 |
| Thomaidou, L | 1 |
| Loupa, H | 1 |
| Feris, J | 1 |
| Moledina, N | 1 |
| Rodriguez, WJ | 1 |
| Khan, WN | 1 |
| Puig, J | 1 |
| Wiedermann, BL | 1 |
| Ahmad, S | 1 |
| Trujillo, H | 1 |
| Harry, N | 1 |
| Arango, A | 1 |
| Benítez, G | 1 |
| Restrepo, F | 1 |
| Mejía, GI | 1 |
| Castrillón, AL | 1 |
| Schönwald, S | 1 |
| Schoss-Vidensek, Z | 1 |
| Car, V | 1 |
| Krznar, B | 1 |
| Trucchi, E | 1 |
| Trucchi, A | 1 |
| Giannoni, R | 1 |
| Legramandi, C | 1 |
| Fonte, A | 1 |
| Madsen, PO | 1 |
| Nielsen, KT | 1 |
| Graversen, PH | 1 |
| Edelstein, H | 1 |
| Oster, S | 1 |
| Cassano, K | 1 |
| McCabe, R | 1 |
| Yoshida, K | 1 |
| Uchijima, Y | 1 |
| Kobayashi, N | 1 |
| Suwata, J | 1 |
| Nakame, Y | 1 |
| Saitoh, H | 1 |
| Negishi, T | 1 |
| Yamada, T | 1 |
| Kageyama, Y | 1 |
| Kura, N | 1 |
| Rusconi, F | 1 |
| Assael, BM | 1 |
| Boccazzi, A | 1 |
| Colombo, R | 1 |
| Crossignani, RM | 1 |
| Garlaschi, L | 1 |
| Rancilio, L | 1 |
| Neu, HC | 3 |
| Roberts, JA | 1 |
| Lebel, MH | 1 |
| McCracken, GH | 1 |
| Jones, SR | 1 |
| Kimbrough, R | 1 |
| Webb, G | 1 |
| Robbins, MJ | 1 |
| O'Hare, MD | 1 |
| Felmingham, D | 1 |
| Ridgway, GL | 1 |
| Grüneberg, RN | 1 |
| Westenfelder, M | 1 |
| Frankenschmidt, A | 1 |
| Pelz, K | 1 |
| Naber, K | 1 |
| Kees, F | 2 |
| Denk, K | 1 |
| Bauernfeind, A | 1 |
| Grobecker, H | 2 |
| Hahn, LB | 1 |
| Iribarren, M | 1 |
| Barclay, C | 1 |
| Casellas, J | 1 |
| Traballi, C | 1 |
| Farinati, A | 1 |
| Dalet, F | 1 |
| del Río, G | 1 |
| Hoepelman, AI | 1 |
| Bakker, LJ | 1 |
| Verhoef, J | 1 |
| Raz, R | 1 |
| Flatau, E | 1 |
| Sudarsky, M | 1 |
| Keness, J | 1 |
| Deger, F | 1 |
| Douchamps, J | 1 |
| Freschi, E | 1 |
| Thys, JP | 1 |
| Nève, P | 1 |
| Herchuelz, A | 1 |
| Cocimano, V | 1 |
| Casetta, G | 1 |
| Piana, P | 1 |
| Tizzani, A | 1 |
| Peddie, BA | 1 |
| Wood, MJ | 1 |
| Smith, G | 1 |
| Farrell, ID | 1 |
| Sklavunu-Tsurutsoglu, S | 1 |
| Gatzola-Karaveli, M | 1 |
| Hitoglu-Makedu, A | 1 |
| Paradelis, AG | 1 |
| Tsurutsoglu, G | 1 |
| Kotilainen, P | 1 |
| Huovinen, P | 1 |
| Hänninen, P | 1 |
| Ohmori, H | 1 |
| Sakai, S | 1 |
| Niijima, T | 1 |
| Kishi, H | 1 |
| Ohkoshi, M | 1 |
| Kawamura, N | 1 |
| Naide, Y | 1 |
| Nishiura, T | 1 |
| Fontana, G | 1 |
| Laudi, M | 1 |
| Carlone, NA | 1 |
| Savoia, D | 1 |
| Donadio, C | 1 |
| Tramonti, G | 1 |
| Garcea, G | 1 |
| Lorusso, P | 1 |
| Lucchetti, A | 1 |
| Giordani, R | 1 |
| Pierotti, R | 1 |
| Falcone, G | 1 |
| Bianchi, C | 1 |
| Muzzonigro, G | 1 |
| Minardi, D | 1 |
| Caraceni, E | 1 |
| Villanova, A | 1 |
| Polito, M | 1 |
| Naber, KG | 1 |
| Dette, GA | 1 |
| Knothe, H | 1 |
| Gioè, FP | 1 |
| Arcara, M | 1 |
| Gucciardi, A | 1 |
| Stutman, HR | 1 |
| Chartrand, SA | 1 |
| Tolentino, T | 1 |
| Friedhoff, L | 1 |
| Marks, MI | 1 |
| Fraschini, F | 1 |
| Scaglione, F | 1 |
| Alessandria, M | 1 |
| Gattei, G | 1 |
| Caramia, G | 1 |
| Compagnoni, L | 1 |
| Pettinari, A | 1 |
| Gregorini, S | 1 |
| LeFrock, JL | 1 |
| Smith, BR | 1 |
| Chandrasekar, P | 1 |
| Rolston, KV | 1 |
| Molavi, A | 1 |
| Kannangara, W | 1 |
| Yamamoto, K | 2 |
| Shimizu, S | 1 |
| Yamamoto, A | 1 |
| Naka, K | 1 |
| Tatsuta, I | 1 |
| Ishikawa, O | 1 |
| Ohshika, Y | 1 |
| Umesaki, N | 1 |
| Sugawa, T | 1 |
| Hatase, T | 1 |
| Katabuchi, H | 1 |
| Watanabe, H | 1 |
| Umezu, J | 1 |
| Yakushiji, M | 1 |
| Kato, T | 1 |
| Romero-Vivas, J | 1 |
| Rodríguez-Créixems, M | 1 |
| Bouza, E | 1 |
| Hellín, T | 1 |
| Guerrero, A | 1 |
| García de la Torre, M | 1 |
| Sykes, RB | 1 |
| Bonner, DP | 1 |
| Swabb, EA | 1 |
| Henry, SA | 1 |
| Bendush, CB | 1 |
| Childs, SJ | 1 |
| Phipps, JH | 1 |
| Osborn, DE | 1 |
| Mitchell, CJ | 1 |
| Scully, BE | 1 |
| Simons, WJ | 1 |
| Lee, TJ | 1 |
| Moriguchi, R | 1 |
| Yamagoshi, T | 1 |
| Nagakubo, I | 1 |
| Aoki, S | 1 |
| Kobashi, H | 1 |
| Aihara, R | 1 |
| Nishioka, A | 1 |
| Oohara, K | 1 |
| Okamoto, T | 1 |
| Niino, M | 1 |
| Kida, K | 1 |
| Matsuda, H | 1 |
| Murase, M | 1 |
10 reviews available for aztreonam and Urinary Tract Infections
| Article | Year |
|---|---|
Aztreonam.
Topics: Aztreonam; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Humans; Urinary Tract | 1993 |
Aztreonam.
Topics: Aztreonam; Bacterial Infections; Costs and Cost Analysis; Female; Genital Diseases, Female; Humans; | 1992 |
The use of aztreonam in pediatric patients: a review.
Topics: Adult; Aztreonam; Bacterial Infections; Gram-Negative Aerobic Bacteria; Humans; Infant, Newborn; Men | 1991 |
The role of aztreonam in treatment of complicated urinary tract infections in children.
Topics: Aztreonam; Child; Humans; Urinary Tract Infections | 1989 |
Aztreonam: critical evaluation of the first monobactam antibiotic in treatment of urinary tract infections.
Topics: Aztreonam; Clinical Trials as Topic; Humans; United States; Urinary Tract Infections | 1988 |
Aztreonam: the first monobactam.
Topics: Aztreonam; Bacterial Infections; Gram-Negative Bacteria; Humans; Respiratory Tract Infections; Sepsi | 1988 |
Role of aztreonam in urinary tract infections.
Topics: Aztreonam; Bacteriuria; Clinical Trials as Topic; Cross Infection; Drug Resistance, Microbial; Human | 1988 |
Aztreonam: review of the clinical experience and potential uses in pediatrics.
Topics: Adolescent; Aztreonam; Bacterial Infections; Child; Child, Preschool; Cross Reactions; Cystic Fibros | 1988 |
UTIs and two new antibiotics in the elderly.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Cilastatin; Cilastatin, Imipenem Drug Combination; Cycloprop | 1988 |
Review of the clinical pharmacology of the monobactam antibiotic aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; Child; Drug Administration Schedule; Feces; Gram-Negative Aerobic | 1985 |
32 trials available for aztreonam and Urinary Tract Infections
| Article | Year |
|---|---|
Aztreonam compared with gentamicin for treatment of serious urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacteria; Clinical Trials as Topic; Femal | 1984 |
[Clinical evaluation of azthreonam in severe urinary tract infections].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Female; Humans; | 1984 |
Clinical experience with aztreonam in urinary and respiratory tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Escherichia coli Infections | 1984 |
Aztreonam versus cefamandole in the treatment of urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacteria; Cefamandole; Female; Follow-Up | 1984 |
Prophylaxis of urinary tract infection in renal transplantation: comparison of three different protocols using ceftriaxone-cloxacillin, aztreonam-cloxacillin, or aztreonam-amoxycillin-clavulanic acid.
Topics: Adult; Amoxicillin; Aztreonam; Ceftriaxone; Cloxacillin; Drug Therapy, Combination; Female; Follow-U | 1995 |
[Aztreonam as monotherapy in urinary tract infections with a systemic repercussion in patients with a relative contraindication for the use of aminoglycosides].
Topics: Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Chi-Square Distribution; | 1993 |
A comparative trial of aztreonam versus gentamicin in the treatment of urinary tract infections.
Topics: Adult; Aged; Aztreonam; Female; Gentamicins; Humans; Male; Middle Aged; Prospective Studies; Urinary | 1992 |
[A randomized controlled study on imipenem/cilastatin sodium in comparison to aztreonam + lincomycin in treating severe infections in patients with malignant tumors or hematological diseases].
Topics: Adolescent; Adult; Aged; Aztreonam; Cilastatin; Drug Therapy, Combination; Female; Hematologic Disea | 1992 |
Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aztreonam; Bacteremia; Citrobacter; Cross Infection; | 1992 |
A comparative study on aztreonam, ceftazidime and amikacin in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Aztreonam; Bacterial Infections; Ceftazidime; Female; Huma | 1991 |
[Clinical evaluation of the combination of carumonam and cefotiam in the treatment of complicated urinary tract infection].
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Cefotiam; Drug Synergism; Drug Therapy, Combination; Fema | 1991 |
A single dose of aztreonam in the prevention of urinary tract infections in elderly catheterized patients.
Topics: Aged; Aged, 80 and over; Aztreonam; Diabetes Complications; Double-Blind Method; Female; Humans; Mal | 1990 |
[Clinical evaluation of the combination of carumonam and fosfomycin in the treatment of complicated urinary tract infection].
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Chronic Disease; Drug Therapy, Combination; Female; Fosfo | 1990 |
[Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Aztreonam; Clinical Trials as Topic; Cystitis; F | 1989 |
A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacterial Infecti | 1989 |
Multicenter comparative study of aztreonam and gentamicin in the treatment of renal and urinary tract infections.
Topics: Adult; Aged; Ambulatory Care; Aztreonam; Bacterial Infections; Female; Gentamicins; Humans; Injectio | 1989 |
Aztreonam in the treatment of urinary tract infections: a multicenter trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Child; Cross Infection; | 1989 |
[Clinical reevaluation of aztreonam (AZT) on urinary tract infections].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Clinical Trials as Topic; Female; Humans; Inf | 1989 |
[Clinical evaluation of aztreonam (AZT) in the treatment of complicated urinary tract infections].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Drug Evaluation; Female; Humans; Infusions, I | 1989 |
[An Italian multicenter study on the efficacy and tolerability of aztreonam in the treatment of urinary tract infections].
Topics: Adolescent; Adult; Aged; Aztreonam; Bacterial Infections; Child; Drug Tolerance; Female; Humans; Mal | 1988 |
Aztreonam: critical evaluation of the first monobactam antibiotic in treatment of urinary tract infections.
Topics: Aztreonam; Clinical Trials as Topic; Humans; United States; Urinary Tract Infections | 1988 |
Carumonam versus ceftazidime for urinary tract infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Ceftazidime; Drug Tolerance; Female; | 1988 |
[Clinical efficacy of aztreonam in patients with complicated urinary tract infections].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Aztreonam; Bacterial Infections; Che | 1988 |
Role of aztreonam in urinary tract infections.
Topics: Aztreonam; Bacteriuria; Clinical Trials as Topic; Cross Infection; Drug Resistance, Microbial; Human | 1988 |
Carumonam and cefotiam in the treatment of complicated urinary tract infection (UTI): a randomized study.
Topics: Anti-Bacterial Agents; Aztreonam; Cefotiam; Clinical Trials as Topic; Female; Humans; Male; Middle A | 1987 |
Carumonam versus ceftazidime: in vitro activity, pharmacokinetics in elderly patients, safety and therapeutic efficacy in the treatment of complicated urinary tract infections.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Bacteria; Ceftazidime; Clinical Trials as Topic; Female; Hum | 1987 |
Comparative study of Ro 17-2301 (AMA-1080) and amikacin in complicated urinary tract infections.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacteria; Clinical Trials as Topic; Double-Blind M | 1987 |
Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Drug Evaluation; Female; Gentamicins; Humans; Injecti | 1988 |
[Well-controlled comparative study on aztreonam and cefoperazone in the treatment of complicated urinary tract infections].
Topics: Adolescent; Adult; Aged; Aztreonam; Bacteriuria; Cefoperazone; Clinical Trials as Topic; Female; Gra | 1986 |
Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Aztreonam; Cefotaxime; Cross Infection; Female; Gram-Negative Bacteria; Gram-Positive B | 1986 |
Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
Topics: Abdomen; Adult; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Clini | 1985 |
Aztreonam in the treatment of urinary tract infection.
Topics: Anti-Bacterial Agents; Aztreonam; Cefamandole; Cross Infection; Drug Resistance, Microbial; Escheric | 1985 |
48 other studies available for aztreonam and Urinary Tract Infections
| Article | Year |
|---|---|
The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections.
Topics: Ampicillin; Anti-Bacterial Agents; Aztreonam; Cefepime; Ceftazidime; Ceftriaxone; Ciprofloxacin; Dru | 2022 |
High prevalence of β-lactam and fluoroquinolone resistance in various phylotypes of Escherichia coli isolates from urinary tract infections in Jiroft city, Iran.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; | 2023 |
Multi-drug resistance pattern of bacterial isolates from urinary tract infection.
Topics: Anti-Bacterial Agents; Aztreonam; Cefepime; Escherichia coli; Humans; Nitrofurantoin; Urinary Tract | 2023 |
Clinical outcomes in elderly patients with infections caused by NDM-producing Klebsiella pneumoniae: results from a real-life retrospective single center study in an endemic area.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Female; Humans; Klebsiella Infections; Klebsiella pne | 2023 |
Impact of SEP-1 on broad-spectrum combination antibiotic therapy in the emergency department.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Centers for Medicare and Medi | 2020 |
CTX-M-137, a hybrid of CTX-M-14-like and CTX-M-15-like β-lactamases identified in an Escherichia coli clinical isolate.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; | 2014 |
Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; be | 2014 |
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
Topics: Aminoglycosides; Ampicillin; Anti-Infective Agents; Aztreonam; Cefixime; Cefozopran; Cefpirome; Cefp | 2006 |
Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Dru | 2008 |
[The efficacy of aztreonam in a "bolus dose" in the therapy of urinary tract infections in neonates].
Topics: Aztreonam; Drug Evaluation; Female; Humans; Infant, Newborn; Injections, Intramuscular; Male; Remiss | 1993 |
The incidence and beta-lactam resistance of Proteus vulgaris in hospital infections: the last decade.
Topics: Ampicillin Resistance; Anti-Bacterial Agents; Aztreonam; Bacteremia; beta-Lactamases; Cephalosporins | 1991 |
[Bacterial combination effect between carumonam and eight other antibiotics].
Topics: Animals; Aztreonam; Dibekacin; Drug Resistance, Microbial; Drug Synergism; Escherichia coli; Female; | 1990 |
[Aztreonam and aminoglycosides in the therapy of urinary infections associated with renal calculosis].
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacteria; Drug Evaluatio | 1989 |
Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
Topics: Aztreonam; Bacterial Infections; Gram-Negative Bacteria; Humans; Infant, Newborn; Infant, Premature, | 1989 |
Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections.
Topics: Aztreonam; Bacterial Infections; Child; Child, Preschool; Female; Gastroenteritis; Gram-Negative Bac | 1989 |
Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients.
Topics: Abscess; Aerobiosis; Appendix; Aztreonam; Bacterial Infections; Cecal Diseases; Child, Preschool; Fe | 1989 |
The clinical use of aztreonam.
Topics: Adult; Aged; Aztreonam; Bacterial Infections; Female; Humans; Male; Middle Aged; Respiratory Tract I | 1989 |
[Tissue concentration of aztreonam in organs of the urogenital system].
Topics: Aztreonam; Humans; Kidney; Male; Prostate; Testis; Tissue Distribution; Urinary Bladder; Urinary Tra | 1988 |
"Short-term" prophylaxis by aztreonam in prevention of post-operative infections in patients undergoing transurethral surgery.
Topics: Aztreonam; Humans; Postoperative Complications; Premedication; Urethra; Urinary Tract Infections; Ur | 1988 |
Aztreonam in the treatment of severe urinary tract infections in pediatric patients.
Topics: Adolescent; Aztreonam; Child; Child, Preschool; Citrobacter; Enterobacter; Enterobacteriaceae Infect | 1986 |
In vitro activity of aztreonam, cefuroxime and ceftazidime against gram-negative rods isolated from hospital patients with urinary tract infection.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftazidime; Cefuroxime; Gram-Negative Bacteria; Humans; Microbial | 1987 |
[Aztreonam: prevention of bacteremia in urologic surgery in patients with urinary infection].
Topics: Adult; Aged; Aztreonam; Female; Gram-Negative Bacteria; Humans; Male; Middle Aged; Postoperative Com | 1988 |
Clinical evaluation of aztreonam for serious gram-negative bacterial infections.
Topics: Adult; Aged; Aztreonam; Bacterial Infections; Bone Diseases; Drug Evaluation; Female; Gastrointestin | 1988 |
Aztreonam in the treatment of serious gram-negative infections in the elderly.
Topics: Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Female; Gram-Negative Aerobic Bacteria; Hu | 1988 |
Incidence of urinary tract infections following endoscopic surgery in immunodepressed patients treated with thymostimulin.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aztreonam; Female; Humans; Immune Tolerance; Male; | 1987 |
In vitro studies with aztreonam, a new monobactam antibiotic.
Topics: Anti-Infective Agents, Urinary; Aztreonam; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tes | 1986 |
Aztreonam for severe infections.
Topics: Aztreonam; Bacterial Infections; Female; Humans; Male; Middle Aged; Sepsis; Urinary Tract Infections | 1987 |
Aztreonam in gram-negative infections in children.
Topics: Aztreonam; Bacterial Infections; Child; Child, Preschool; Female; Gram-Negative Bacteria; Humans; In | 1987 |
Carumonam in the treatment of severe and complicated urinary tract infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacteria; Female; Humans; Male; Urinary T | 1987 |
Treatment of urinary infections: clinical perspectives.
Topics: Adult; Aztreonam; Cinoxacin; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Klebsiell | 1987 |
Azthreonam in the treatment of urinary tract infection: evaluation of efficacy, renal effects and nephrotoxicity.
Topics: Adult; Aged; Aztreonam; Enzymes; Female; Humans; Injections, Intramuscular; Kidney Diseases; Kidney | 1987 |
Effectiveness and tolerability of aztreonam in urinary tract infection caused by multiresistant bacteria.
Topics: Adult; Aged; Aztreonam; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Male; Middle Ag | 1987 |
[Aztreonam in urinary tract infections].
Topics: Adult; Aged; Aztreonam; Drug Evaluation; Female; Humans; Male; Middle Aged; Urinary Tract Infections | 1986 |
Aztreonam therapy for serious gram-negative infections in children.
Topics: Aztreonam; Bacteria, Aerobic; Bacterial Infections; Child, Preschool; Humans; Infant; Infant, Newbor | 1986 |
Use of aztreonam in patients suffering from urinary tract infections with contraindications for the use of aminoglycosides.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Female; Humans; Male; Middle Aged; U | 1986 |
[Efficiency and possibility of the use of aztreonam in bacterial infections caused by gram-negative organisms].
Topics: Aztreonam; Child; Child, Preschool; Female; Gram-Negative Bacteria; Humans; Infant; Male; Respirator | 1986 |
Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Female; Gram-Negative Bacteria; Hum | 1987 |
[Fundamental and clinical studies on aztreonam in the field of obstetrics and gynecology].
Topics: Adult; Aged; Aztreonam; Bacterial Infections; Drug Evaluation; Female; Genital Diseases, Female; Gen | 1985 |
[Clinical studies on aztreonam in infections in obstetrics and gynecology].
Topics: Adult; Aged; Aztreonam; Bacterial Infections; Drug Evaluation; Female; Humans; Infusions, Parenteral | 1985 |
Evaluation of aztreonam in the treatment of severe bacterial infections.
Topics: Adolescent; Adult; Aged; Aztreonam; Bacterial Infections; Child; Humans; Middle Aged; Osteomyelitis; | 1985 |
Aztreonam: the first monobactam.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Bacterial Proteins; beta-Lactamases | 1985 |
Treatment of urinary tract infections with aztreonam.
Topics: Aztreonam; Enterococcus faecalis; Humans; Pseudomonas; Urinary Tract Infections | 1985 |
Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infectio | 1985 |
Treatment of gram-negative infections with aztreonam.
Topics: Abscess; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; | 1985 |
Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Topics: Abdomen; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Biliary Trac | 1985 |
[Clinical evaluation of aztreonam for complicated urinary tract infection].
Topics: Adult; Aged; Aztreonam; Drug Evaluation; Female; Humans; Infusions, Parenteral; Male; Middle Aged; U | 1985 |
[Clinical experience with aztreonam in the pediatric field].
Topics: Acute Disease; Age Factors; Aztreonam; Bacteria; Bronchopneumonia; Child; Child, Preschool; Drug Eva | 1985 |
[Clinical study on aztreonam in pediatrics].
Topics: Age Factors; Aztreonam; Child; Child, Preschool; Drug Evaluation; Enteritis; Female; Humans; Infant; | 1985 |